Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960469 | 0.86 | SLC6A2 (0.41) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3952567 | 0.83 | MEN1 (0.40) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3980389 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3979375 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3972796 | 0.80 | SLC6A2 (0.54) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3956463 | 0.80 | SLC6A2 (0.54) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3974416 | 0.80 | SLC6A2 (0.54) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL3986431 | 0.79 | SLC6A4 (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3960765 | 0.78 | MEN1 (0.41) | SLC6A2SLC6A4MEN1KMT2AOPRM1 | |
| SCHEMBL5700658 | 0.78 | SLC6A2 (0.43) | SLC6A2SLC6A4LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1687288-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | SLC6A2 125/4885SLC6A4 72/4885LMNA 1679/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | SLC6A2 108/4885SLC6A4 31/4885LMNA 1605/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | SLC6A2 53/4885SLC6A4 38/4885LMNA 2465/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | SLC6A2 115/4885SLC6A4 82/4885LMNA 1130/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A4 44/4885LMNA 667/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A4 44/4885LMNA 667/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | SLC6A2 63/4885SLC6A4 41/4885LMNA 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.